302 related articles for article (PubMed ID: 10326741)
1. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
Carbon C; Poole MD
J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
3. The macrolides: erythromycin, clarithromycin, and azithromycin.
Alvarez-Elcoro S; Enzler MJ
Mayo Clin Proc; 1999 Jun; 74(6):613-34. PubMed ID: 10377939
[TBL] [Abstract][Full Text] [Related]
4. Microbiologic activity of the newer macrolide antibiotics.
McCracken GH
Pediatr Infect Dis J; 1997 Apr; 16(4):432-7. PubMed ID: 9109155
[TBL] [Abstract][Full Text] [Related]
5. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Berry V; Thorburn CE; Knott SJ; Woodnutt G
Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
[TBL] [Abstract][Full Text] [Related]
6. History of macrolide use in pediatrics.
Klein JO
Pediatr Infect Dis J; 1997 Apr; 16(4):427-31. PubMed ID: 9109154
[TBL] [Abstract][Full Text] [Related]
7. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
[TBL] [Abstract][Full Text] [Related]
8. The newer macrolides. Azithromycin and clarithromycin.
Zuckerman JM; Kaye KM
Infect Dis Clin North Am; 1995 Sep; 9(3):731-45. PubMed ID: 7490441
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
[TBL] [Abstract][Full Text] [Related]
10. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.
Langtry HD; Brogden RN
Drugs; 1997 Jun; 53(6):973-1004. PubMed ID: 9179528
[TBL] [Abstract][Full Text] [Related]
11. [The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2001 and 2002].
Melo-Cristino J; Serrano N;
Rev Port Pneumol; 2003; 9(4):293-310. PubMed ID: 19771688
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of bacterial resistance to macrolides.
Halpern MT; Schmier JK; Snyder LM; Asche C; Sarocco PW; Lavin B; Nieman R; Mandell LA
J Antimicrob Chemother; 2005 May; 55(5):748-57. PubMed ID: 15772147
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
14. Azithromycin and clarithromycin: overview and comparison with erythromycin.
Whitman MS; Tunkel AR
Infect Control Hosp Epidemiol; 1992 Jun; 13(6):357-68. PubMed ID: 1320067
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN
Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
[TBL] [Abstract][Full Text] [Related]
16. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.
Aberg JA; Wong MK; Flamm R; Notario GF; Jacobson MA
HIV Clin Trials; 2001; 2(6):453-9. PubMed ID: 11742432
[TBL] [Abstract][Full Text] [Related]
17. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from patients in primary hospitals in Shanghai from 2007 to 2010].
Zhou CM; Hu BJ; Gao XD; Bao R; Xie HM; Huang SL; Tao LL; He LX
Zhonghua Jie He He Hu Xi Za Zhi; 2013 May; 36(5):346-50. PubMed ID: 24047808
[TBL] [Abstract][Full Text] [Related]
18. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
Burgess DS; Hastings RW; Horan JL
Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.
Van Asselt GJ; Sloos JH; Mouton RP; Van Boven CP; Van de Klundert JA
J Med Microbiol; 1995 Nov; 43(5):386-91. PubMed ID: 7563004
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
